NASDAQ:OCAT - Ocata Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$8.47 0.00 (0.00 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$8.47
Today's Range$8.47 - $8.47
52-Week Range$3.06 - $8.71
VolumeN/A
Average Volume656,469 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Ocata Therapeutics (NASDAQ OCAT) News Headlines

Source:
DateHeadline
Global Stem Cells IndustryGlobal Stem Cells Industry
www.bizjournals.com - July 12 at 3:56 PM
The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 22.1%The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 22.1%
www.bizjournals.com - May 8 at 9:52 AM
BioTime, Inc.: An Undervalued Regenerative Medicine CompanyBioTime, Inc.: An Undervalued Regenerative Medicine Company
seekingalpha.com - April 9 at 10:17 AM
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee ChairKala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
www.bizjournals.com - March 5 at 10:31 AM
Critical Analysis: Ocata Therapeutics (OCAT) vs. Its CompetitorsCritical Analysis: Ocata Therapeutics (OCAT) vs. Its Competitors
www.americanbankingnews.com - January 27 at 3:32 AM
Comparing Ocata Therapeutics (OCAT) & Its CompetitorsComparing Ocata Therapeutics (OCAT) & Its Competitors
www.americanbankingnews.com - January 4 at 5:04 PM
Astellas sues former research partners, claiming usurpation of stem cell tech - Boston Business JournalAstellas sues former research partners, claiming 'usurpation' of stem cell tech - Boston Business Journal
www.bizjournals.com - November 14 at 9:01 PM
Reviewing Ocata Therapeutics (OCAT) and Madrigal Pharmaceuticals (MDGL)Reviewing Ocata Therapeutics (OCAT) and Madrigal Pharmaceuticals (MDGL)
www.americanbankingnews.com - November 12 at 1:10 AM
Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology - PR Newswire (press release)Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology - PR Newswire (press release)
www.prnewswire.com - October 21 at 7:19 AM
How Flagships newest startup is pursuing a holy grail of biotech - Boston Business JournalHow Flagship's newest startup is pursuing a 'holy grail' of biotech - Boston Business Journal
www.bizjournals.com - June 23 at 8:42 AM
Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies - PR Newswire (press release)Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies - PR Newswire (press release)
www.prnewswire.com - June 22 at 6:08 AM
Global Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and MarketsGlobal Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets
www.bizjournals.com - May 5 at 7:14 PM
Pharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - BloombergPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - Bloomberg
www.bloomberg.com - December 1 at 12:08 AM
Pharma CEO Hunts New Trophy After Prostate Cancer BlockbusterPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster
www.bloomberg.com - November 30 at 11:50 AM
BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release)BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release)
www.businesswire.com - November 10 at 6:24 PM
Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.comApplied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.com
www.thestreet.com - September 20 at 11:49 AM
Chinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog)Chinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog)
www.bizjournals.com - September 13 at 11:24 AM
Pharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and AsiaPharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia
www.bizjournals.com - September 6 at 11:18 AM
Key Executives for Ocata Therapeutics, Inc.Key Executives for Ocata Therapeutics, Inc.
www.bloomberg.com - August 23 at 6:47 PM
Ocata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking AlphaOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha
seekingalpha.com - January 26 at 2:31 PM
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.